AUXL 32.66 Auxilium Pharmaceuticals $AUXL Hit a 52 week high of 33.13 Closing the day 11/05/14 at 32.66 +0.08 +0.25% With a day low of 32.26 and a total volume of 1,644,293.
AUXL Recent Posts: http://investorshangout.com/Auxilium-Pharmace...UXL-53427/
AUXL Auxilium Pharmaceuticals Recent Headline News
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 102.77 (-1.06), ENDP: 68.70 (+0.03), AUXL: 32.66 (+0.08), SHPG: 198.61 (+2.99), DNDN: 0.93 (-0.05), SNSS: 1.70 (+0.02), ABBV: 62.54 (-0.12), SNY: 45.70 (+0.21), MNKD: 5.67 (-0.25), XOMA: 4.00 (-0.18)
60.1% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Nov 03, 10:57AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 60.09% as of today's recent price of $32.33.
AUXL: 32.66 (+0.08)
Flamel Technologies (FLML) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:38AM CST
Flamel Technologies (FLML) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down nearly 15% in the past one-month time frame.
FLML: 11.76 (-0.27), AUXL: 32.66 (+0.08), IG: 9.55 (-0.40), BIOD: 1.50 (+0.01)
Auxilium Pharmaceuticals, Inc. to Present XIAFLEX and STENDRA Data at SMSNA Scientific Meeting
PR Newswire - Mon Nov 03, 5:00AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD) and STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) will be presented at the upcoming 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) being held in Miami from November 20-23, 2014.
AUXL: 32.66 (+0.08)
Pacira Down on Wider than Expected Q3 Loss, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:00PM CDT
Pacira Pharmaceuticals' (PCRX) third-quarter 2014 loss of 5 cents per share was wider than the Zacks Consensus Estimate of a loss of a penny but much narrower than the year-ago loss of 41 cents per share.
LCI: 53.15 (-3.10), VRX: 131.91 (-1.70), AUXL: 32.66 (+0.08), PCRX: 87.71 (-2.27)
The Zacks Analyst Blog Highlights:Endo International, Auxilium Pharmaceuticals, Infinity Pharmaceuticals and Karyopharm Therapeutics
PR Newswire - Thu Oct 30, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Endo International (Nasdaq:ENDP-Free Report), Auxilium Pharmaceuticals Inc. (Nasdaq:AUXL-Free Report), Infinity Pharmaceuticals, Inc. (Nasdaq:INFI-Free Report) and Karyopharm Therapeutics, Inc. (Nasdaq:KPTI-Free Report).
AUXL: 32.66 (+0.08), INFI: 12.29 (-0.49)
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 3.95 (-0.03), VRX: 131.91 (-1.70), AUXL: 32.66 (+0.08), BMY: 57.82 (-0.02)
Auxilium reports 3Q loss
Automated Insights - Thu Oct 30, 6:07AM CDT
CHESTERBROOK, Pa. (AP) _ Auxilium Pharmaceuticals Inc. (AUXL) on Thursday reported a third-quarter loss of $32.7 million.
AUXL: 32.66 (+0.08)
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.
AUXL: 32.66 (+0.08)
54.9% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Oct 27, 9:37AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 54.94% as of today's recent price of $31.29.
AUXL: 32.66 (+0.08)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 68.70 (+0.03), PRGO: 158.50 (-1.35), AUXL: 32.66 (+0.08), DEPO: 14.92 (-0.40), AMPE: 3.73 (-0.07)
Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 3:10PM CDT
Omeros Corporation (OMER) suffered a pipeline setback with the company announcing the suspension of enrollment in a phase II study evaluating OMS824.
MDVN: 102.77 (-1.06), AUXL: 32.66 (+0.08), LGND: 55.29 (-0.98), OMER: 17.24 (+0.12)
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
PR Newswire - Mon Oct 20, 4:30PM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same hand during a single treatment visit.
AUXL: 32.66 (+0.08)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Auxilium Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Sun Oct 19, 5:26PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auxilium Pharmaceuticals, Inc. ("Auxilium" or the "Company"
(Nasdaq: AUXL) relating to the proposed buyout of the Company by Endo International plc ("Endo" .
AUXL: 32.66 (+0.08)
AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Over the Proposed Sale of the Company to Endo International PLC -AUXL
PR Newswire - Fri Oct 17, 5:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company" (Nasdaq: AUXL) for potential breaches of fiduciary duties in connection with the sale of the Company to Endo International Plc ("Endo" for approximately $2.6 billion. The Company's stockholders may elect to receive a combination of $16.625 in cash plus 0.2440 Endo ordinary shares, $33.25 in cash, or 0.4880 Endo ordinary shares for each share of Auxilium stock they own.
AUXL: 32.66 (+0.08)
Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:30PM CDT
Tekmira Pharmaceuticals Corporation (TKMR) presented encouraging preclinical data on its hepatitis B infection candidate, TKM-HBV.
MDVN: 102.77 (-1.06), AUXL: 32.66 (+0.08), LGND: 55.29 (-0.98), TKMR: 15.12 (-1.13)
Lifshitz & Miller Law Firm Announces Investigation of Apco Oil & Gas International Inc., Arrowhead Research Corporation, Auxilium Pharmaceuticals, Inc., EveryWare Global, Inc., and Gentiva Health Services, Inc.
PR Newswire - Wed Oct 15, 4:23PM CDT
Apco Oil & Gas International Inc.
APAGF: 14.25 (+0.29), ARWR: 6.19 (-0.22), AUXL: 32.66 (+0.08), EVRY: 1.06 (-0.05), GTIV: 19.55 (+0.21)
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 111.59 (-2.51), ALNY: 88.01 (-1.98), GILD: 106.05 (-3.67), SRPT: 15.17 (-1.21), AUXL: 32.66 (+0.08), AMGN: 158.94 (-1.47), ABBV: 62.54 (-0.12)
AUXL Recent Posts: http://investorshangout.com/Auxilium-Pharmace...UXL-53427/
AUXL Auxilium Pharmaceuticals Recent Headline News
3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 102.77 (-1.06), ENDP: 68.70 (+0.03), AUXL: 32.66 (+0.08), SHPG: 198.61 (+2.99), DNDN: 0.93 (-0.05), SNSS: 1.70 (+0.02), ABBV: 62.54 (-0.12), SNY: 45.70 (+0.21), MNKD: 5.67 (-0.25), XOMA: 4.00 (-0.18)
60.1% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Nov 03, 10:57AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 60.09% as of today's recent price of $32.33.
AUXL: 32.66 (+0.08)
Flamel Technologies (FLML) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:38AM CST
Flamel Technologies (FLML) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down nearly 15% in the past one-month time frame.
FLML: 11.76 (-0.27), AUXL: 32.66 (+0.08), IG: 9.55 (-0.40), BIOD: 1.50 (+0.01)
Auxilium Pharmaceuticals, Inc. to Present XIAFLEX and STENDRA Data at SMSNA Scientific Meeting
PR Newswire - Mon Nov 03, 5:00AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that data evaluating the use of XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of Peyronie's disease (PD) and STENDRA® (avanafil) tablets for the treatment of erectile dysfunction (ED) will be presented at the upcoming 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) being held in Miami from November 20-23, 2014.
AUXL: 32.66 (+0.08)
Pacira Down on Wider than Expected Q3 Loss, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:00PM CDT
Pacira Pharmaceuticals' (PCRX) third-quarter 2014 loss of 5 cents per share was wider than the Zacks Consensus Estimate of a loss of a penny but much narrower than the year-ago loss of 41 cents per share.
LCI: 53.15 (-3.10), VRX: 131.91 (-1.70), AUXL: 32.66 (+0.08), PCRX: 87.71 (-2.27)
The Zacks Analyst Blog Highlights:Endo International, Auxilium Pharmaceuticals, Infinity Pharmaceuticals and Karyopharm Therapeutics
PR Newswire - Thu Oct 30, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Endo International (Nasdaq:ENDP-Free Report), Auxilium Pharmaceuticals Inc. (Nasdaq:AUXL-Free Report), Infinity Pharmaceuticals, Inc. (Nasdaq:INFI-Free Report) and Karyopharm Therapeutics, Inc. (Nasdaq:KPTI-Free Report).
AUXL: 32.66 (+0.08), INFI: 12.29 (-0.49)
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 3.95 (-0.03), VRX: 131.91 (-1.70), AUXL: 32.66 (+0.08), BMY: 57.82 (-0.02)
Auxilium reports 3Q loss
Automated Insights - Thu Oct 30, 6:07AM CDT
CHESTERBROOK, Pa. (AP) _ Auxilium Pharmaceuticals Inc. (AUXL) on Thursday reported a third-quarter loss of $32.7 million.
AUXL: 32.66 (+0.08)
Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 5:00AM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the third quarter ending September 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.
AUXL: 32.66 (+0.08)
54.9% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Oct 27, 9:37AM CDT
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 54.94% as of today's recent price of $31.29.
AUXL: 32.66 (+0.08)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 68.70 (+0.03), PRGO: 158.50 (-1.35), AUXL: 32.66 (+0.08), DEPO: 14.92 (-0.40), AMPE: 3.73 (-0.07)
Omeros Falls as Enrollment for OMS824 Study is Suspended - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 3:10PM CDT
Omeros Corporation (OMER) suffered a pipeline setback with the company announcing the suspension of enrollment in a phase II study evaluating OMS824.
MDVN: 102.77 (-1.06), AUXL: 32.66 (+0.08), LGND: 55.29 (-0.98), OMER: 17.24 (+0.12)
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
PR Newswire - Mon Oct 20, 4:30PM CDT
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for XIAFLEX® (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same hand during a single treatment visit.
AUXL: 32.66 (+0.08)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Auxilium Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Sun Oct 19, 5:26PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Auxilium Pharmaceuticals, Inc. ("Auxilium" or the "Company"
(Nasdaq: AUXL) relating to the proposed buyout of the Company by Endo International plc ("Endo" . AUXL: 32.66 (+0.08)
AUXILIUM PHARMACEUTICALS INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auxilium Pharmaceuticals Inc. Over the Proposed Sale of the Company to Endo International PLC -AUXL
PR Newswire - Fri Oct 17, 5:30PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or the "Company"
(Nasdaq: AUXL) for potential breaches of fiduciary duties in connection with the sale of the Company to Endo International Plc ("Endo" for approximately $2.6 billion. The Company's stockholders may elect to receive a combination of $16.625 in cash plus 0.2440 Endo ordinary shares, $33.25 in cash, or 0.4880 Endo ordinary shares for each share of Auxilium stock they own. AUXL: 32.66 (+0.08)
Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 4:30PM CDT
Tekmira Pharmaceuticals Corporation (TKMR) presented encouraging preclinical data on its hepatitis B infection candidate, TKM-HBV.
MDVN: 102.77 (-1.06), AUXL: 32.66 (+0.08), LGND: 55.29 (-0.98), TKMR: 15.12 (-1.13)
Lifshitz & Miller Law Firm Announces Investigation of Apco Oil & Gas International Inc., Arrowhead Research Corporation, Auxilium Pharmaceuticals, Inc., EveryWare Global, Inc., and Gentiva Health Services, Inc.
PR Newswire - Wed Oct 15, 4:23PM CDT
Apco Oil & Gas International Inc.
APAGF: 14.25 (+0.29), ARWR: 6.19 (-0.22), AUXL: 32.66 (+0.08), EVRY: 1.06 (-0.05), GTIV: 19.55 (+0.21)
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 111.59 (-2.51), ALNY: 88.01 (-1.98), GILD: 106.05 (-3.67), SRPT: 15.17 (-1.21), AUXL: 32.66 (+0.08), AMGN: 158.94 (-1.47), ABBV: 62.54 (-0.12)
